In Grade C component preparation areas, dissolution of Calmtop RTU Inj. (Irinotecan) Pharma Grade API for injectable concentrate is ordered with sorbitol and lactic acid before aseptic filtration. The target concentration is 20 mg/mL expressed as irinotecan hydrochloride trihydrate, equivalent to 17.33 mg/mL irinotecan base. Temperature during dissolution is maintained at 15–25 °C because the lactone ring of the camptothecin nucleus hydrolyzes rapidly at alkaline pH and at elevated temperature. Lactic acid is added to achieve a final pH of 3.5, with an in-process control range of 3.0–3.8; this pH window retains the pharmacologically active closed-lactone form and reduces carboxylate generation during filling. Sorbitol is used at 45 mg/mL to adjust tonicity without exceeding the osmolality threshold for peripheral infusion. The solution is sparged with nitrogen to reduce oxidative degradation of the quinoline moiety. After 0.45 µm pre-filtration and two 0.22 µm PVDF sterilizing filters arranged in series, the liquid is filled into USP Type I borosilicate glass vials under Grade A laminar airflow. Terminal sterilization is not employed because the hydrolysis rate constant increases sharply above 100 °C, and autoclave cycle validation cannot demonstrate preservation of the lactone fraction. The finished injectable is tested for bacterial endotoxins by USP <85>, sterility by USP <71>, particulate matter by USP <788>, and pH by USP <791>.

What Limits Terminal Sterilization of Irinotecan Hydrochloride Injection Concentrates?

Steam sterilization at 121 °C and 15 psig is excluded from the process design because the camptothecin lactone ring undergoes pH-dependent hydrolysis, and the reaction rate in aqueous media increases with temperature. If the formulation is autoclaved, the pH drifts upward as the buffer capacity of lactic acid is consumed, shifting the lactone–carboxylate equilibrium toward the open-ring carboxylate form. The closed lactone species is the pharmacologically relevant form; a drop in lactone fraction below 85% at final release is considered a process failure. The aseptic route is therefore mandatory under 21 CFR 211.167 and ISO 13408-1:2008. Aseptic filtration uses a sterilizing-grade membrane with bacterial retention performance validated per ASTM F838-20 using Brevundimonas diminuta ATCC 19146 at a challenge level of at least 10⁷ CFU/cm². Pressure across the filter train is limited to 2.0 bar because excessive differential pressure can generate local heating and shear-induced particle shedding. Filter integrity testing by diffusion flow or bubble point is performed before and after filling, with maximum allowed diffusion flow values supplied by the filter manufacturer for the specific lot.

For a 40 mg/vial lyophilized presentation, mannitol is dissolved in Water for Injection at 40–50 mg/mL as a crystalline bulking agent before adding irinotecan hydrochloride trihydrate and lactic acid to a final pH of 3.2–3.6. The solution is filled into 20 mL USP Type I clear glass vials at 5 mL fill volume, then partially stoppered with bromobutyl closures and loaded onto lyophilizer shelves pre-cooled to 5 °C. Freezing is conducted at −40 °C for at least 4 h to ensure complete crystallization of mannitol and to avoid amorphous collapse. Primary drying is controlled at a shelf temperature of −35 °C and a chamber pressure of 150 mTorr; product temperature is monitored by Type T thermocouples and Pirani gauge comparison. The endpoint is determined by a pressure rise test below 30 mTorr over 60 s. Secondary drying is ramped to 40 °C over 6 h and held for 6 h to achieve residual moisture of ≤2.0% by USP <921> Method Ic. The vials are backfilled with nitrogen to 600–800 mbar and sealed. Reconstitution with sterile water must produce a clear solution within 2 min and a pH of 3.0–3.8; cake cracking, meltback, or residual moisture above 3.0% triggers batch rejection because those defects are associated with lactone ring hydrolysis during storage.

Direct Compression of Irinotecan HCl Tablets Requires Microenvironmental Acidifiers Rather Than Alkaline Lubricants

Before direct compression of irinotecan HCl tablets, the pre-blend is prepared from irinotecan hydrochloride trihydrate, microcrystalline cellulose, lactose monohydrate, crospovidone, and colloidal silicon dioxide passed through a 0.8 mm sieve to break agglomerates. The binder is dry because aqueous wet granulation would expose the API to water at pH values above 5.5, accelerating lactone ring opening. Citric acid anhydrous at 2–3 wt% is included as a microenvironmental acidifier; the aqueous slurry pH of the final blend is controlled to 3.5–4.5 by USP <791>. Lubrication is performed with sodium stearyl fumarate at 0.5 wt% rather than magnesium stearate because the alkaline surface of magnesium stearate can generate localized pH above 6.5 at particle contact points. Tablets are compressed on a rotary press with 10 mm round standard concave B-tooling at a compression force of 8–14 kN, producing hardness of 5–7 kp and friability below 0.8% per USP <1216>. Compression speed is limited to 30–50 rpm to avoid excessive turret dwell time and shear-induced amorphization. Dissolution testing per USP <711> in 0.1 N hydrochloric acid is used as a discriminating medium because the closed lactone form remains stable in acidic conditions. Content uniformity is verified by USP <905> with acceptance value not exceeding 15.0.

In a high-containment isolator with negative differential pressure to the surrounding room of at least −15 Pa and air changes not fewer than 30 per hour, capsule filling of irinotecan hydrochloride trihydrate is performed as described in ISO 14644-7. The API is sieved through a 0.6 mm screen and blended with lactose monohydrate, microcrystalline cellulose, and croscarmellose sodium at 15–20 °C and ≤35% RH. The final blend target is a bulk density of 0.55–0.65 g/cm³, a Carr index of 15–20%, and a Hausner ratio below 1.25, measured by USP <1174>. A dosator-type capsule filling machine with size 3 hard gelatin capsules is set to a fill weight of 120 mg for a 20 mg strength, giving a fill weight variation below ±5%. Empty capsule shells are pre-conditioned at 40–50% RH to maintain shell brittleness within acceptable limits; bone-dry shells below 35% RH suffer from cracking during high-speed filling. Content uniformity is evaluated by USP <905> and dissolution by USP <711> in 0.1 N hydrochloric acid with a target of not less than 75% dissolved at 45 min as a screening condition, not as a regulatory release limit. The filled capsules are polished and metal-checked before packaging in aluminum-aluminum blister film to limit moisture ingress.

When Irinotecan HCl Is Dry Granulated for Oral Suspension Sachets, Reconstitution pH Must Remain Below 4.0

When oral suspension sachets are required, roller compaction is substituted for wet granulation because the camptothecin lactone ring is susceptible to hydrolysis at the water activities encountered in a fluidized-bed granulator. The pre-blend of API, lactose monohydrate, and microcrystalline cellulose is forced through a roller compactor with 25 mm knurled rolls at a specific compaction force of 12–15 kN/cm and roll speed of 5–8 rpm. Ribbon density is maintained at 1.1–1.3 g/cm³ because softer ribbons produce excess fines and harder ribbons reduce re-dispersibility. The milled granulate is passed through a 1.0 mm screen and a 150–850 µm target fraction is collected; fines below 75 µm are limited to ≤15%. Anhydrous citric acid at 2.0 wt% is blended into the granules to ensure the reconstituted suspension pH remains ≤4.0, which is below the pH range where the carboxylate form becomes dominant. Xanthan gum at 0.3–0.5 wt% is used as a suspending agent; after reconstitution in 100 mL of purified water, the viscosity is 50–100 mPa·s at 25 °C when measured by a rotational viscometer at 50 rpm. Sachet filling is performed under 25 °C and ≤30% RH. The granulate is tested for water content by USP <921>, microbial limits by USP <61> and USP <62>, and dispersion uniformity by a validated in-house method.

Managing PVC Infusion Bag Contact After Dilution of Irinotecan Concentrate

Dilution of 20 mg/mL irinotecan concentrate into 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP yields final concentrations between 0.12 mg/mL and 2.8 mg/mL. The diluted admixture remains a weakly acidic solution because the lactic acid buffer in the concentrate controls pH between 3.0 and 4.0 in the infusion bag. Contact with polyvinyl chloride containers is not the primary degradation driver for irinotecan, but leachable testing is required under ICH Q3C and extractable profiling under USP <665> where infusion ports or tubing sets contain plasticizers. Infusion sets made of low-density polyethylene or polypropylene are preferred when prolonged contact times are expected because lower surface adsorption reduces irinotecan loss to the bag wall. The admixture should be protected from light during administration because photodegradation of the camptothecin chromophore is temperature-independent and accelerates above 3000 lux UV/visible irradiation per ICH Q1B. Particulate matter is controlled by USP <788> in the finished injection and by in-use filtration through a 0.2 µm inline filter during administration where the drug product labeling permits. The pharmacy beyond-use date is assigned according to USP <797>, and the specific storage temperature range of 2–8 °C or 15–25 °C must be justified by compounding facility environmental monitoring data.